alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit32

Certification Pursuant to 18 U.S.C. Section 1350 asAdoptedPursuant to Section 906 of the Sarbanes-Oxley Act of2002

In connection with the Annual Report ofAXS-One Inc. (the ‘‘Company’’) on Form 10-K forthe year ended December  31,  2005, as filed with theSecurities and Exchange Commission on the date hereof (the‘‘Report’’), each of the undersigned officersof the Company certifies pursuant to 18 U.S.C. Section1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

|  |          |                                                                                                                     |
|--|----------|---------------------------------------------------------------------------------------------------------------------|
|  | 1.  | The Report fully complies with therequirements of Section 13(a) or 15(d) of the Securities Exchange Actof 1934, and |

|  |          |                                                                                                                                                    |
|--|----------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|  | 2.  | The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company. |

|                                             |  |              |  |                                                                           |  |  |  |  |  |  |
|---------------------------------------------|--|--------------|--|---------------------------------------------------------------------------|--|--|--|--|--|--|
|                                        |  | AXS-ONE INC. |
| Date:    March23,  2006 |  | By:          |  | /s/ William P.Lyons                                                       |
|                                        |  |         |  | William P. Lyons Chairman ofthe Board and Chief Executive Officer         |
|                                        |  | By:          |  | /s/ JosephDwyer                                                           |
|                                        |  |         |  | Joseph DwyerExecutive VicePresident, Chief Financial Officer,andTreasurer |
|                                             |

----
<PAGE>

                              ACCOUNTANTS' CONSENT
                              --------------------

The Board of Directors
Hardin Bancorp. Inc.:

We consent to the incorporation by reference in the registration statements on
Form S-8 of Hardin Bancorp, Inc. of our report dated May 14, 1997, relating to
the consolidated balance sheets of Hardin Bancorp, Inc. and subsidiaries as of
March 31, 1997 and 1996, and the related consolidated statements of earnings,
stockholders' equity and cash flows for each of the years in the three-year
period ended March 31, 1997, which report appears in the annual report on Form
10-KSB of Hardin Bancorp, Inc. for the fiscal year ended March 31, 1997 filed
pursuant to the Securities Exchange Act of 1934, as amended.

Kansas City, Missouri
June 26, 1997
**Exhibit 32.2**

SECTION 1350CERTIFICATION 

        Inconnection with the accompanying Quarterly Report on Form 10-Q of Penn TreatyAmerican Corporation (the “Company”) for the period ended March 31, 2005 asfiled with the Securities and Exchange Commission, I, Mark D. Cloutier, Senior VicePresident and Chief Financial Officer of****the Company**,** certify pursuant to 18U.S.C. Section §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Actof 2002 that to the best of my knowledge:
#### § 822.38 What reports must I submit to you?

You must submit interim and final reports as specified in your approved postmarket surveillance plan. In addition, we may ask you to submit additional information when we believe that the information is necessary for the protection of the public health and implementation of the act. We will also state the reason or purpose for the request and how we will use the information.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3620 Methadone test system. ( a ) *Identification.* A methadone test system is a device intended to measure methadone, an addictive narcotic pain-relieving drug, in serum and urine. Measurements obtained by this device are used in the diagnosis and treatment of methadone use or overdose and to determine compliance with regulations in methadone maintenance treatment.
( b ) *Classification.* Class II (special controls). A methadone test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
[52 FR 16122, May 1, 1987, as amended at 84 FR 71798, Dec. 30, 2019]
§ 522.2582 Triflupromazine. ( a ) *Specifications.* Each milliliter of solution contains 20 milligrams (mg) of triflupromazine hydrochloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount* — ( i ) *Dogs.* Administer by intravenous injection at a dosage of 0.5 to 1 mg per pound of body weight daily, or by intramuscular injection at a dosage of 1 to 2 mg per pound of body weight daily.
( ii ) *Cats.* Administer by intramuscular injection at a dosage of 2 to 4 mg per pound of body weight daily.
( iii ) *Horses.* Administer by intravenous or intramuscular injection at a dosage of 10 to 15 mg per 100 pounds of body weight daily to a maximum dose of 100 mg.
( 2 ) *Indications for use.* For use in dogs, cats, and horses to relieve anxiety and to help control psychomotor overactivity as well as to increase the tolerance of animals to pain and pruritus. The drug is indicated in various office and clinical procedures which require the aid of a tranquilizer, antiemetic, or preanesthetic.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16197, Mar. 25, 2014]
# C_2015346EN.01002601.xml

| 19.10.2015 | EN | Official Journal of the European Union | C 346/26 |
| --- | --- | --- | --- |

19.10.2015

EN

Official Journal of the European Union

C 346/26

---

Judgment of the General Court of 3 September 2015 — iNET24 Holding v OHIM (IDIRECT24)

(Case T-225/14) (1)

1

((Community trade mark - International registration designating the European Community - Word mark IDIRECT24 - Absolute ground for refusal - Lack of distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009 - Obligation to state reasons - Article 75 of Regulation No 207/2009))

(2015/C 346/30)

Language of the case: German

Parties

Parties

Applicant: iNET24 Holding AG (Feusisberg, Switzerland) (represented by: S. Kirschstein-Freund, B. Breitinger and V. Dalichau, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (trade marks and designs) (represented by: initially by A. Pohlmann and S. Hanne, acting as Agents)

Defendant:

Re:

Re:

Action brought against the decision of the Fifth Board of Appeal of OHIM of 4 February 2014 (Case R 1867/2013-5), concerning the international registration designating the European Community of word mark IDIRECT24.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders iNET24 Holding AG to pay the costs. |
| --- | --- |

2.

Orders iNET24 Holding AG to pay the costs.

---

(1)  OJ C 184, 16.6.2014.

1

---
Order entered March 6, 2013

In The 

## Court of Appeals **Fifth District of Texas at Dallas**
No. 05
- 12
- 01559
- CV
CHERRY PETERSEN LAND RY ALBERT L . L . P . , Appellant
V. ERWIN CRUZ, M.D., Appellee On Appeal from the 101st Judicial District Court Dallas County, Texas Trial Court Cause No. 10
- 16274 

### O RDER The Court has before it appellant’s March 1, 2013 second unopposed motion for extension of time to file brief of appellant. The Court GRANTS the motion and ORDERS appellant to file its brief by April 8, 2013. No further extensions will be granted without a showing of exceptional circumstances.

/s/ ELIZABETH LANG

- MIERS JUSTICE
IN THE SUPREME COURT OF PENNSYLVANIA

WESTERN DISTRICT

IN RE: ESTATE OF PETER J. CARUSO, III

GERALDINE CARUSO

v.

SANDRA CARUSO, EXECUTRIX OF THE ESTATE OF PETER J. CARUSO, III

PETITION OF: SANDRA A. CARUSO :

:

:

:

:

:

:

:

:

:

:

: No. 43 WAL 2023

Petition for Allowance of Appeal from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 21st day of August, 2023

, the Petition for Allowance of Appeal is

GRANTED . The issue, as stated by petitioner, is:

Where a non

- party to a partnership agreement is not a signatory to the agreement and is not a third

- party beneficiary of it and where a partnership agreement does not permit assignment, whether the Court’s review is necessary to clarify the circumstances where a n on

- party could be permitted to “step into the shoes” of a party to an agreement and to enforce contractual rights as if that individual were a party to the agreement.
<PAGE>

                                                                    EXHIBIT 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



               In connection with the Annual Report of Day International Group,
Inc (the "Company") on Form 10-K for the period ending December 31, 2002 as
filed with the Securities and Exchange Commission on the date hereof (the
"Report"), I, Dennis R. Wolters, Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to my knowledge:

               (1)     The Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

               (2)     The information contained in the Report fairly presents,
in all material respects, the financial position and results of operations of
the Company.

               A signed original of this written statement required by Section
906 has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.




/s/ Dennis R. Wolters
--------------------------------------------
Dennis R. Wolters
Chief Executive Officer
March 28, 2003
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1370 Human growth hormone test system. ( a ) *Identification.* A human growth hormone test system is a device intended to measure the levels of human growth hormone in plasma. Human growth hormone measurements are used in the diagnosis and treatment of disorders involving the anterior lobe of the pituitary gland.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2306, Jan. 14, 2000]
§ 582.5230 Calcium sulfate. ( a ) *Product.* Calcium sulfate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
<PAGE>   1
                               September 22, 1998




Pan Environmental Corporation
19239 Aurora Avenue North
Shoreline, WA  98133-3930

Ladies and Gentlemen:

         With respect to the Registration Statement on Form S-8 of Pan
Environmental, Corporation (the "Company") in connection with the registration
of 490,250 shares of common stock, par value $0.001, ("Common Stock") which have
been reserved for issuance pursuant to various employment agreements and service
provider agreements, We are of the opinion that the Common Stock when issued in
accordance with the terms and provisions of the agreements will be duly
authorized, legally issued, fully paid and nonassessable.

         This opinion is limited to the laws of the State of Delaware, and we
disclaim any opinion as to the laws of any other jurisdiction. We further
disclaim any opinion as to any statute, rule, regulation, ordinance, order or
other promulgation of any other jurisdiction or any regional or local
governmental body or as to any related judicial or administrative opinion. We
express no opinion as to the applicable choice of law provisions contained in
any agreement.

         This opinion is rendered to you in connection with the issuance of the
Common Stock and is solely for your benefit. This opinion may not be relied upon
by any other person, firm, corporation or other entity for any purpose, without
prior written consent.

         We hereby consent to the filing of this opinion as Exhibit 5 to the
Registration Statement.

                                Very truly yours,



                                /s/ MCGUIRE, WOODS BATTLE & BOOTHE LLP
                                McGuire Woods Battle & Boothe LLP
Fw: Updated MATS RIA for OMB Distribution (Message 2 of 3) 

 RobertJ Wayland 

 to: Cortney_Higgins 

 11/23/2011 02:41 PM 

 Cc: Bill Maxwell 

 

Cortney - 

Attached are the remaining chapters of the revised/updated RIA. 

Hope you have a great Thanksgiving and get some time to spend with family 

and friends! 

Happy Thanksgiving! 

bob 

Robert J. Wayland, Ph.D. 

Leader, Energy Strategies Group 

U.S. Environmental Protection Agency 

Office of Air Quality Planning & Standards 

Sector Policies and Programs Division 

Mail Code D243-01 

RTP, NC 27711 

 

Phone: (919) 541-1045 

Cell: (919) 306-2290 

Fax: (919) 541-5450 

e-mail: wayland.robertj@epa.gov 

********************************************************* 

DRAFT/Deliberative Document -- FOIA Exempt 

********************************************************* 

Chapter 6_EmploymentImpactAnalysis_1123.docx 

Chapter 7_StatutoryandExecutiveOrderAnalyses_1123.doc 

Chapter 8_SummaryofCostsandBenefits_1123.doc
**Final Listing of Questionnaire Files for Steam Electric Rulemaking Record**

**Plant ID** 07070 **Removed from Public**  **(Non-CBI) Docket** **1 Copyright** 

**Flag 2**  **File Name Description**  

### 07070\07070_Certification Statement.pdf Plant certification statement 

### x 07070\07070_Checklist.xls EPA Technical Review Checklist Workbook



### 07070\07070_Completeness_Checklist.xls EPA Completeness Review Checklist 

### 07070\07070_HardcopyLog.doc EPA log of hardcopy documents submitted 

### x 07070\07070_PartA.xls Plant submitted survey file 

### x 07070\07070_PartB.xls Plant submitted survey file 

### x 07070\07070_PartC.xls Plant submitted survey file 

### x 07070\07070_PartD.xls Plant submitted survey file 

### x 07070\07070_PartE.xls Plant submitted survey file 

### x 07070\07070_PartF.xls Plant submitted survey file 

### x 07070\07070_PartG.xls Plant submitted survey file 

### x 07070\07070_PartH.xls Plant submitted survey file



### 07070\Supporting Documents\07070_A2-3 Site EIS Excerpt.pdf Plant submitted supplemental files to the survey 

### x 07070\Supporting Documents\07070_A5-2 Site Map.pdf Plant submitted supplemental files to the survey 

### x 07070\Supporting Documents\07070_A5-3 Water Balance Diagram.pdf Plant submitted supplemental files to the survey 

### x 07070\Supporting Documents\07070_D3-1 Pond System Diagram.pdf Plant submitted supplemental files to the survey 

### x 07070\Supporting Documents\07070_F5-6 Landfill Monitoring Well Diagram.pdf Plant submitted supplemental files to the survey

1Final reviewed survey responses are located in the Steam Electric Technical Questionnaire Database

. 2Copyright documents are available from the docket.
# C_2015221EN.01001501.xml

| 6.7.2015 | EN | Official Journal of the European Union | C 221/15 |
| --- | --- | --- | --- |

6.7.2015

EN

Official Journal of the European Union

C 221/15

---

Judgment of the General Court of 21 May 2015 — Urb Rulmenti Suceava SA v OHIM — Adiguzel (URB)

(Case T-635/14) (1)

1

((Community trade mark - Invalidity proceedings - Figurative Community trade mark URB - Application for the earlier national mark URB, earlier national collective word mark URB, earlier national collective figurative mark URB and earlier international figurative marks URB - Absolute ground for refusal - No bad faith on the part of the proprietor of the Community trade mark - Article 52(1)(b) of Regulation (EC) No 207/2009 - Relative ground for refusal - No authorisation by the proprietor of the earlier marks - Article 8(1)(b) and Article 53(1)(a) of Regulation No 207/2009 - No infringement of Articles 22(3) and 72(1) of Regulation No 207/2009))

(2015/C 221/20)

Language of the case: English

Parties

Parties

Applicant: Urb Rulmenti Suceava SA (Suceava, Romania) (represented by: I. Burdusel, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: P. Bullock, Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of OHIM, intervening before the General Court: Harun Adiguzel (Diosd, Hungary) (represented by: G. Bozocea, lawyer)

Other party to the proceedings before the Board of Appeal of OHIM, intervening before the General Court:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 23 June 2014 (Case R 1974/2013-4) concerning invalidity proceedings between Urb Rulmenti Suceava SA and Mr Harun Adiguzel.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Urb Rulmenti Suceava SA to pay the costs; |
| --- | --- |

2.

Orders Urb Rulmenti Suceava SA to pay the costs;

| 3. | Orders Mr Harun Adiguzel to bear his own costs. |
| --- | --- |

3.

Orders Mr Harun Adiguzel to bear his own costs.

---

(1)  OJ C 361, 13.10.2014.

1

---
<PAGE>   1
               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

   
We consent to reference to our firm under the caption "Experts" in Amendment No.
2 to the Registration Statement (Form S-3) and related Prospectus of InControl,
Inc. for the registration of 3,769,000 shares of its common stock and to the
incorporation by reference therein of our report dated January 29, 1998, with
respect to the consolidated financial statements of InControl, Inc. included in
its Annual Report (Form 10-K/A) for the year ended December 31, 1997, filed with
the Securities and Exchange Commission.
    

                                                              ERNST & YOUNG LLP



   
Seattle, Washington
July 19, 1998
§ 740.12 Feminine deodorant sprays. ( a ) For the purpose of this section, the term “feminine deodorant spray” means any spray deodorant product whose labeling represents or suggests that the product is for use in the female genital area or for use all over the body.
( b ) The label of a feminine deodorant spray shall bear the following statement: *Caution*—For external use only. Spray at least 8 inches from skin. Do not apply to broken, irritated, or itching skin. Persistent, unusual odor or discharge may indicate conditions for which a physician should be consulted. Discontinue use immediately if rash, irritation, or discomfort develops.
The sentence “Spray at least 8 inches from skin” need not be included in the cautionary statement for products whose expelled contents do not contain a liquified gas propellant such as a halocarbon or hydrocarbon propellant.
( c ) Use of the word “hygiene” or “hygienic” or a similar word or words renders any such product misbranded under section 602(a) of the Federal Food, Drug, and Cosmetic Act. The use of any word or words which represent or suggest that such products have a medical usefulness renders such products misbranded under section 502(a) of the Act and illegal new drugs marketed in violation of section 505 of the Act.
[40 FR 8929, Mar. 3, 1975]
**Exhibit 31.1**

 

**CERTIFICATION OF PRINCIPALEXECUTIVE OFFICER**

 

I, Thomas J. Shaw,certify that:

 

1. I have reviewed thisannual report on Form 10-K/A of Retractable Technologies, Inc.;

 

2. Based on my knowledge,this report does not contain any untrue statement of a material fact or omit tostate a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading withrespect to the period covered by this report;

 

3. Based on my knowledge,the financial statements, and other financial information included in thisreport, fairly present in all material respects the financial condition,results of operations, and cash flows of the registrant as of, and for, theperiods presented in this report;

 

4. The registrant’s othercertifying officer(s) and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and have:

 

a)              Designed suchdisclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;  

 

b)             Evaluated theeffectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered by this reportbased on such evaluation; and

 

c)              Disclosed in thisreport any change in the registrant’s internal control over financial reportingthat occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and 

 

5. Theregistrant’s other certifying officer(s) and I have disclosed, based on ourmost recent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of the registrant’s board ofdirectors (or persons performing the equivalent functions):

 

a) All significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize, and reportfinancial information; and

 

b) Any fraud,whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.

 
| Date: February 26, 2008   |   |   |
|---------------------------|--------|--------|
|                      |   |   |
| /s/ Thomas J.  Shaw       |   |   |
| THOMAS J. SHAW            |   |   |
| PRESIDENT,  CHAIRMAN, AND |   |   |
| CHIEF EXECUTIVE  OFFICER  |   |   |

 

----